National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Amivantamab (Rybrevant®). HTA ID: 22004

Amivantamab (Rybrevant®) is indicated for the treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 17/01/2022
Rapid review completed 03/02/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 23/02/2022
Pre-submission consultation with Applicant 28/03/2022
Current Status Awaiting HTA submission from Applicant